Squarepoint Ops LLC Increases Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN)

Squarepoint Ops LLC raised its stake in Design Therapeutics, Inc. (NASDAQ:DSGN) by 146.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 89,955 shares of the company’s stock after purchasing an additional 53,518 shares during the period. Squarepoint Ops LLC owned 0.16% of Design Therapeutics worth $301,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in DSGN. Vanguard Group Inc. grew its position in shares of Design Therapeutics by 29.0% during the first quarter. Vanguard Group Inc. now owns 1,285,962 shares of the company’s stock worth $5,182,000 after acquiring an additional 288,803 shares during the last quarter. Acadian Asset Management LLC grew its position in shares of Design Therapeutics by 123.3% during the first quarter. Acadian Asset Management LLC now owns 403,546 shares of the company’s stock worth $1,625,000 after acquiring an additional 222,805 shares during the last quarter. Baker BROS. Advisors LP grew its position in shares of Design Therapeutics by 10.8% during the first quarter. Baker BROS. Advisors LP now owns 1,662,120 shares of the company’s stock worth $6,698,000 after acquiring an additional 162,120 shares during the last quarter. GSA Capital Partners LLP grew its position in shares of Design Therapeutics by 199.3% during the first quarter. GSA Capital Partners LLP now owns 216,347 shares of the company’s stock worth $872,000 after acquiring an additional 144,055 shares during the last quarter. Finally, Opaleye Management Inc. purchased a new position in shares of Design Therapeutics during the first quarter worth approximately $456,000. 56.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Royal Bank of Canada restated a “sector perform” rating and set a $4.00 target price on shares of Design Therapeutics in a research report on Tuesday, August 6th.

Design Therapeutics Price Performance

NASDAQ:DSGN opened at $5.00 on Friday. Design Therapeutics, Inc. has a 1-year low of $1.96 and a 1-year high of $6.91. The firm’s fifty day moving average price is $4.95 and its 200 day moving average price is $4.32. The firm has a market cap of $283.10 million, a price-to-earnings ratio of -5.56 and a beta of 1.83.

Design Therapeutics (NASDAQ:DSGN) last released its earnings results on Monday, August 5th. The company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.02. As a group, analysts expect that Design Therapeutics, Inc. will post -0.94 earnings per share for the current fiscal year.

Insider Buying and Selling at Design Therapeutics

In other news, Director Arsani William sold 814,874 shares of Design Therapeutics stock in a transaction on Friday, August 9th. The stock was sold at an average price of $4.25, for a total transaction of $3,463,214.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 31.20% of the stock is owned by corporate insiders.

About Design Therapeutics

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.